

650,000+ Injuries Reported after COVID Vaccines, as Biden, FDA Spar Over Boosters

By Megan Redshaw

Global Research, September 08, 2021

<u>Children's Health Defense</u> 7 September 2021

Theme: Science and Medicine

Region: USA

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at <a>@crg globalresearch.

Data released Friday by the Centers for Disease Control and Prevention (CDC) showed that between Dec. 14, 2020 and Aug. 27, 2021, a total of 650,077 total adverse events were reported to VAERS, including 13,911 deaths — an increase of 284 over the number of deaths reported the previous week.

There were <u>85,971 reports of serious injuries</u>, including deaths, during the same time period — up 1,505 compared with the previous week.

Excluding "<u>foreign reports</u>" filed in VAERS, <u>514,270 adverse events</u>, including <u>6,296 deaths</u> and <u>39,947 serious injuries</u>, were reported in the U.S. between Dec. 14, 2020 and Aug. 27, 2021.

Of the 6,296 U.S. deaths reported as of Aug. 27, <u>13% occurred</u> within 24 hours of vaccination, <u>18% occurred</u> within 48 hours of vaccination and <u>32% occurred</u> in people who experienced an onset of symptoms within 48 hours of being vaccinated.

In the U.S., 366.5 million COVID vaccine doses had been administered as of Aug. 27. This <u>includes</u>: 208 million doses of <u>Pfizer</u>, 145 million doses of <u>Moderna</u> and 14 million doses of <u>Johnson & Johnson</u> (J&J).



Search Results

From the 8/27/2021 release of VAERS data:

Found 650,077 cases where Vaccine is COVID19

| Evert Dutanese | ↑↓ | |
|-------------------------|-----------|----------|
| | Count | Percent |
| Death | 13,611 | 2.141 |
| Permanent Disability | 18,068 | 2,785 |
| Office Visit | 160,856 | 15.975 |
| Emergency Room | 67 | 0.011 |
| Energency Decim/Recen | 78,100 | 0.79 |
| Hospitalized | 56.743 | 8.73* |
| Hospitalized, Prolonged | 160 | 0.005 |
| Receivered | 212,754 | 32,725 |
| Birth Defect | 406 | 0.081 |
| Life Threatening | 14,327 | 2.2 |
| Not Sertion | 214.218 | 42.181 |
| TOTAL | 1 773,408 | E 108.60 |

The data come directly from reports submitted to the <u>Vaccine Adverse Event Reporting System</u>(VAERS), the primary government-funded system for reporting adverse vaccine reactions in the U.S.

Every Friday, <u>VAERS</u> makes public all vaccine injury reports received as of a specified date, usually about a week prior to the release date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.

This week's U.S. data for 12- to 17-year-olds show:

■ <u>18,523</u> total adverse events, including <u>1,091 rated as serious</u> and <u>18 reported deaths</u>. Two of the 18 deaths were suicides.

The most recent reported deaths include a 15-year-old boy (VAERS I.D. <u>1498080</u>) who previously had COVID, was diagnosed with cardiomyopathy in May 2021 and died four days after receiving his second dose of Pfizer's vaccine on June 18, when he collapsed on the soccer field and went into ventricular tachycardia; and a 13-year-old girl (VAERS I.D. <u>1505250</u>) who died after suffering a heart condition after receiving her first dose of Pfizer.

- Other deaths include two <u>13-year-old boys</u> (VAERS I.D. <u>1406840</u> and <u>1431289</u>) who died two days after receiving a Pfizer vaccine, a 13-year-old boy who died after receiving Moderna (VAERS I.D. <u>1463061</u>), three 15-year-olds (VAERS I.D. <u>1187918</u>, <u>1382906</u> and <u>1242573</u>), five 16-year-olds (VAERS I.D. <u>1420630</u>, <u>1466009</u>, <u>1225942</u>, <u>1475434</u>, and <u>1386841</u>) and three 17-year-olds (VAERS I.D. <u>1199455</u>, <u>1388042</u> and <u>1420762</u>).
- 2,715 reports of anaphylaxis among 12- to 17-year-olds with 99% of cases

attributed to Pfizer's vaccine.

- <u>457 reports</u> of myocarditis and pericarditis (heart inflammation) with <u>450 cases</u> attributed to Pfizer's vaccine.
- <u>97 reports</u> of blood clotting disorders, with all cases attributed to Pfizer.

This week's total U.S. VAERS data, from Dec. 14, 2020 to Aug. 27, 2021, for all age groups combined, show:

- 20% of deaths were related to cardiac disorders.
- 54% of those who died were male, 43% were female and the remaining death reports did not include gender of the deceased.
- The <u>average age</u> of death was 73.1.
- As of Aug. 27, 3,389 pregnant women reported adverse events related to COVID vaccines, including 1008 reports of miscarriage or premature birth.
- Of the <u>2,689 cases of Bell's Palsy</u> reported, 50% were attributed to <u>Pfizer</u> vaccinations, 43% to <u>Moderna</u> and 7% to <u>[&]</u>.
- 545 reports of <u>Guillain-Barré Syndrome</u>, with 39% of cases <u>attributed to Pfizer</u>, 34% to <u>Moderna</u> and 26% to <u>[&]</u>.
- 139,180 reports of anaphylaxis with 42% of cases attributed to <u>Pfizer's vaccine</u>, 51% to <u>Moderna</u> and 7% to <u>[&]</u>.
- 8,751 reports of blood clotting disorders. Of those, 3,721 reports were attributed to Pfizer, 3,188 reports to Moderna and 1,794 reports to J&J.
- 2,242 cases of myocarditis and pericarditis with 1,411 cases attributed to Pfizer,
 741 cases to Moderna and 83 cases to J&J's COVID vaccine.

Two top FDA officials resign amid White House booster controversy

As <u>The Defender reported</u> Sept. 1, two of the FDA's top vaccine officials announced they will leave the agency this fall, raising questions about the Biden administration and the way it sidelined the agency.

According to an email sent Aug. 31 by Dr. Peter Marks, director of the FDA's <u>Center for Biologics Evaluation and Research</u>, to staff members, Dr. Marion Gruber, director of the FDA's vaccines office, will quit at the end of October, and her deputy, Dr. Philip Krause, will leave in November.

Gruber and Krause were upset about the Biden administration's <u>recent announcement</u> that adults should get a <u>COVID</u> booster eight months after they received a second shot, people familiar with the decision told The New York Times.

Neither believed there was enough data to justify offering <u>booster shots</u> yet, the sources said, and both viewed the announcement, amplified by Biden, as pressure on the FDA to quickly authorize them.

U.S. health regulators also said there isn't enough data to <u>recommend boosters</u> for the general population, yet the White House has moved forward with its plan to offer a third dose of Pfizer or Moderna by the week of Sept. 20 — even though that plan requires authorization from the FDA and CDC first.

FDA advisory committee to hold meeting on COVID vaccine boosters, days before

White House scheduled the roll-out to begin

The FDA <u>announced</u> its Vaccines and Related Biological Products Advisory Committee will hold a virtual advisory meeting Sept. 17, to discuss Pfizer-BioNTech's COVID application for boosters — just days before the shots are to become available to the general population.

The committee's director, Dr. Peter Marks, said "a transparent, thorough and objective review of the data by the FDA is critical so that the medical community and the public continue to have confidence in the safety and <u>effectiveness</u> of COVID-19 vaccines."

The FDA plans to livestream the meeting on the <u>agency's YouTube channel</u>. The meeting also will be webcast from the FDA website.

Moments before the FDA released the announcement, Moderna said it had submitted an application to offer booster doses of its COVID vaccine, <u>CNN reported</u>.

According to CDC data, 955,000 Americans have already <u>received additional vaccine doses</u>, though it's unclear how many of those were technically authorized.

CDC endorses full approval for Pfizer and BioNTech's COVID vaccine

An advisory panel to the CDC last week <u>unanimously endorsed</u> the FDA's full approval of the Pfizer and BioNTech COVID vaccine for people 16 years and older, and the CDC immediately adopted the committee's recommendation.

The endorsement by the CDC's Advisory Committee on Immunization Practices came after the FDA on Aug. 23 <u>granted full approval</u> to Pfizer's "mRNA vaccine, which is being marketed as Comirnaty."

The CDC statement made no mention of the <u>Comirnaty brand</u>, but referred to Pfizer-BioNTech's "licensed" vaccine — even though the <u>FDA approval</u> was limited specifically to the drugmaker's Comirnaty vaccine.

UK panel does not recommend COVID vaccines for healthy children 12 to 15 years old

Britain's vaccine advisers said they would not recommend vaccination of healthy 12- to 15-year-olds against COVID, preferring a precautionary approach due to the potential for vaccinated teens to develop <u>heart inflammation</u>, <u>Reuters reported</u>.

The Joint Committee on Vaccination and Immunisation also said children were at such a <u>low</u> risk from the virus that vaccines would offer only a marginal benefit.

The British government said it would consult medical advisers to look at other factors before making a final decision. The UK's four chief medical officers have been asked to consider the wider impact on schools and society.

The Joint Committee on Vaccination and Immunisation did advise widening the existing vaccine program to include an extra 200,000 teenagers with specific underlying conditions, including chronic heart, lung and liver conditions that put those teens at much higher risk of COVID than healthy children.

More than 100 Ontario youth sent to hospital for vaccine-related heart problems

A <u>report</u> released last week by Public Health Ontario showed the incidence of heart inflammation following mRNA vaccination was significantly more prevalent in young people.

As of Aug. 7, there were 106 incidents of myocarditis and pericarditis in people under the age of 25 in Ontario — slightly more than half of the total of all such incidents. Thirty-one cases occurred in the 12- to 17-year age group and 75 cases in 18- to 24-year-olds. Eighty percent of all cases were in males.

According to the <u>report</u>, the rate of heart inflammation was higher following the second dose of an mRNA vaccine, particularly for those receiving the Moderna vaccine as the second dose of the series, regardless of the product used for the first dose.

Public Health Ontario added the <u>reporting rate for heart inflammation</u> in those 18 to 24 was seven times higher with Moderna than with Pfizer. Pfizer is currently the only vaccine authorized for use in 12- to 17-year-olds in Ontario.

Largest observational study shows natural immunity is better than vaccineinduced immunity

According to a <u>new study</u> comparing natural immunity gained through previous SARS-CoV-2 infection to vaccine-induced immunity afforded by the Pfizer mRNA vaccine, people with natural immunity had longer lasting and stronger protection from SARS-CoV-2 infection, symptomatic disease and hospitalization from the <u>Delta variant</u>.

The study, <u>published</u> Aug. 25 on medRxiv, is the largest observational study to date and used data from Israel — one of the most highly vaccinated countries in the world.

Researchers <u>examined</u> medical records of 673,676 Israelis 16 years and older — charting their infections, symptoms and hospitalizations between June 1 and Aug. 14, when the Delta variant predominated in Israel.

The study found in two analyses that people who had never been infected with SARS-CoV-2 but were vaccinated in January and February were six to 13 times more likely to experience <u>breakthrough infection</u> with the Delta variant compared to unvaccinated people who were previously infected with SARS-CoV-2.

Researchers also found a significantly increased risk of asymptomatic disease in those who had been vaccinated.

Woman experiences rapid onset of rare brain disease after second Pfizer shot, dies within three months

Cheryl Cohen (VAERS ID <u>1535217</u>), a healthy 64-year-old woman from Florida, died three months after her second dose of <u>Pfizer's COVID vaccine</u> from sudden-onset <u>Creutzfeldt-Jakob Disease</u>(CJD), a rare, degenerative and fatal brain disorder she developed soon after she was vaccinated.

In an exclusive <u>interview with The Defender</u>, Gianni Cohen said her mother experienced her first episode indicating something was neurologically wrong with her 11 days after her second Pfizer dose. Her initial symptoms included severe headaches, mass confusion and

brain fog.

After being hospitalized for 10 days, Cohen returned home where her symptoms progressed and her condition rapidly deteriorated. On June 19, Cohen was hospitalized again for a severe headache, after which she was diagnosed with CJD. She died July 22.

Cohen's medical team said the onset of CJD could be tied to the <u>COVID vaccine</u>. Dr. Andrea Folds, one of the internal medicine physicians from Aventura Hospital who oversaw Cohen's case, wrote a case report. The report, submitted Sept. 2 to <u>American College of Physicians Journal</u>, is awaiting approval for publication.

WHO says it's monitoring a new COVID variant called 'Mu'

The World Health Organization (WHO) is monitoring a new COVID variant called "Mu," which the agency says has mutations that have the potential to evade immunity provided by a previous COVID infection or vaccination, <u>CNBC reported</u>.

Mu — known by scientists as B.1.621 — was added to the <u>WHO's list of variants "of interest"</u> on Aug. 30, the international health organization said in its weekly COVID epidemiological report published late Tuesday.

The variant contains genetic mutations that indicate natural immunity, current vaccines or monoclonal antibody treatments may not work as well against it as they do against the original ancestral virus, the WHO said.

The Mu strain needs further study to confirm whether it will prove to be more contagious, more deadly, or more resistant to current vaccines and treatments.

183 days and counting, CDC ignores The Defender's inquiries

According to the <u>CDC website</u>, "the CDC follows up on any report of death to request additional information and learn more about what occurred and to determine whether the death was a result of the vaccine or unrelated."

On March 8, <u>The Defender</u> contacted the CDC with a <u>written list of questions</u> about reported deaths and injuries related to COVID vaccines. We have made repeated attempts, by phone and email, to obtain a response to our questions.

Despite multiple phone and email communications with many people at the CDC, and despite being told that our request was in the system and that someone would respond, we have not yet received answers to any of the questions we submitted. It has been 183 days since we sent our first email to the CDC requesting information.

<u>Children's Health Defense</u> asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following <u>these three steps</u>.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums, etc.

Megan Redshaw is a freelance reporter for The Defender. She has a background in political science, a law degree and extensive training in natural health.

Featured image is from CHD

The original source of this article is <u>Children's Health Defense</u> Copyright © <u>Megan Redshaw</u>, <u>Children's Health Defense</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Megan Redshaw

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca